Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Description
Rosuvastatin was first developed by Japanese company Shionogi & Co., Ltd. in the late 1980s. In Jun. 1998, Shionogi & Co., Ltd. transferred the right to develop, market and sell Rosuvastatin worldwide to AstraZeneca. The development code of Rosuvastatin by AstraZeneca is ZD-4522. Rosuvastatin was first approved in the Netherlands on Nov. 7, 2002, approved by the Health Council of Canada in Feb. 2003, and by the FDA on Aug. 12, 2003. The trade name of AstraZeneca’s branded Rosuvastatin is Crestor.
After Rosuvastatin was launched, its sales value grew sharply. Rosuvastatin has become a key product of statins. In 2012, Rosuvastatin became the number one lipid-lowering drug in the world with a sales value of USD 6.2 billion.
With the improvement of living standards and the change in diet, from 1978 to 2018, Chinese people’s blood lipid levels kept rising, and the incidence of dyslipidemia increased significantly. The overall incidence of dyslipidemia in Chinese adults is up to about 40%. As dyslipidemia is a major cause of the development of coronary heart disease, strokes and other atherosclerotic lesions, active treatment of hyperlipidemia can reduce the incidence of these diseases. In China, Rosuvastatin is used to treat primary hypercholesterolemia (Type IIa, including heterozygous familial hypercholesterolemia) or mixed dyslipidemia (Type IIb) that cannot be properly controlled via diet control and non-drug treatments (e.g. sports therapy and weight loss). In the treatment of homozygous familial hypercholesterolemia, it complements the diet control and other lipid-lowering measures (such as LDL removal), or serves as an alternative when these measures do not work.
According to the, Rosuvastatin has been growing rapidly since it entered China, with its sales revenue increasing from less than CNY 2 million in 2007 to more than CNY 1.1 billion in 2017. At present, China’s Rosuvastatin market is dominated by IPR PHARMACEUTICALS INC. (ASTRAZENECA), Lunan Better Pharmaceutical Co., Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd., Zhejiang Jingxin Pharmaceutical Co., Ltd., etc. Pfizer has the largest market share by sales value which was about 67% in 2017.
It is expected that as more Chinese people suffer from hyperlipidemia, China's Rosuvastatin market will continue to grow in the next few years.
Topics Covered:
- Situation of hyperlipidemia in China
- Market size of Rosuvastatin in China
- Competitive landscape of China's Rosuvastatin market
- Prices of Rosuvastatin in China
- Prospect of China's Rosuvastatin market from 2018 to 2022
Rosuvastatin was first developed by Japanese company Shionogi & Co., Ltd. in the late 1980s. In Jun. 1998, Shionogi & Co., Ltd. transferred the right to develop, market and sell Rosuvastatin worldwide to AstraZeneca. The development code of Rosuvastatin by AstraZeneca is ZD-4522. Rosuvastatin was first approved in the Netherlands on Nov. 7, 2002, approved by the Health Council of Canada in Feb. 2003, and by the FDA on Aug. 12, 2003. The trade name of AstraZeneca’s branded Rosuvastatin is Crestor.
After Rosuvastatin was launched, its sales value grew sharply. Rosuvastatin has become a key product of statins. In 2012, Rosuvastatin became the number one lipid-lowering drug in the world with a sales value of USD 6.2 billion.
With the improvement of living standards and the change in diet, from 1978 to 2018, Chinese people’s blood lipid levels kept rising, and the incidence of dyslipidemia increased significantly. The overall incidence of dyslipidemia in Chinese adults is up to about 40%. As dyslipidemia is a major cause of the development of coronary heart disease, strokes and other atherosclerotic lesions, active treatment of hyperlipidemia can reduce the incidence of these diseases. In China, Rosuvastatin is used to treat primary hypercholesterolemia (Type IIa, including heterozygous familial hypercholesterolemia) or mixed dyslipidemia (Type IIb) that cannot be properly controlled via diet control and non-drug treatments (e.g. sports therapy and weight loss). In the treatment of homozygous familial hypercholesterolemia, it complements the diet control and other lipid-lowering measures (such as LDL removal), or serves as an alternative when these measures do not work.
According to the, Rosuvastatin has been growing rapidly since it entered China, with its sales revenue increasing from less than CNY 2 million in 2007 to more than CNY 1.1 billion in 2017. At present, China’s Rosuvastatin market is dominated by IPR PHARMACEUTICALS INC. (ASTRAZENECA), Lunan Better Pharmaceutical Co., Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd., Zhejiang Jingxin Pharmaceutical Co., Ltd., etc. Pfizer has the largest market share by sales value which was about 67% in 2017.
It is expected that as more Chinese people suffer from hyperlipidemia, China's Rosuvastatin market will continue to grow in the next few years.
Topics Covered:
- Situation of hyperlipidemia in China
- Market size of Rosuvastatin in China
- Competitive landscape of China's Rosuvastatin market
- Prices of Rosuvastatin in China
- Prospect of China's Rosuvastatin market from 2018 to 2022
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
